Sean McCarthy
Chief Executive Officer CytomX Therapeutics
Seminars
Wednesday 14th October 2026
Reviewing the Intentional Design of Varseta-M, a Masked PROBODY® ADC for the Treatment of Colorectal Cancer
- Presenting Phase I clinical data of Varseta-M targeting EpCAM in colorectal cancer
- Connecting masked ADC design correlation to compelling preclinical and clinical profile
- Exploring Varseta-M future clinical development pathway with first-in-class ADC potential in late-late colorectal cancer
